ClinicalTrials.gg
CompletedNCT07372430Updated Nov 16, 2026

Proximal Versus Distal Superior Cluneal Nerve Block in Entrapment Neuropathy

An observational study in Cluneal Syndrome, sponsored by Gaziosmanpasa Research and Education Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Gaziosmanpasa Research and Education Hospital · Observational

How we know

Updated Nov 16, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
59
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Neuralgia with a site in Turkey — 29 open to participants now, 30 under way, none of them phase 3. Neuralgia · Turkey.

Enrollment
32nd of 43
59 · median 96
Started
2025
with 12 others
Observational
43 of 79
15 open now
Registered
56th of 79
by date

Among the 79 studies in Neuralgia with a site in Turkey, this one is the 32nd largest by enrollment of the 43 observational ones that give a count, is one of 13 that started in 2025, is one of 43 observational ones, and was the 56th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

29 of the 79 studies in Neuralgia with a site in Turkey are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Neuralgia with a site in Turkey, or all of them as a file.
02

Study summary

Superior cluneal nerve (SCN) entrapment is an underdiagnosed cause of chronic low back and gluteal pain. Although diagnostic nerve block is considered the gold standard for confirming SCN entrapment, there is no consensus regarding the optimal injection approach. This prospective observational study aims to compare the clinical effectiveness of proximal and distal ultrasound-guided SCN block techniques in patients diagnosed with SCN entrapment. Pain intensity and functional outcomes will be evaluated over the follow-up period to assess differences between the two approaches.

Read the detailed description

The primary objective of this study is to compare the effects of two different ultrasound-guided injection techniques on pain intensity, functional status, neuropathic pain components, and quality of life in patients with suspected superior cluneal nerve (SCN) entrapment. Pain severity will be assessed using the Visual Analog Scale (VAS), functional status using the Oswestry Disability Index (ODI), neuropathic pain components using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), and quality of life using the Short Form-12 (SF-12). The study aims to determine which injection technique provides superior clinical outcomes.

The secondary objective is to evaluate lumbosacral angle, lumbar lordosis angle, pelvic tilt, sacral tilt, and the presence of scoliosis, and to investigate the relationship between these postural and radiological parameters, SCN entrapment, and treatment response.

Through this study, ultrasound-guided injection techniques used in the diagnosis and treatment of SCN entrapment will be comparatively evaluated, addressing an important gap in the current literature and providing high-level scientific evidence to guide clinicians in the management of chronic low back and gluteal pain.

This study is designed as a prospective, assessor-blinded observational study comparing two different ultrasound-guided injection techniques in patients with superior cluneal nerve entrapment confirmed by diagnostic nerve block. The study population will consist of patients presenting to the Algology Outpatient Clinic of Health Sciences University Gaziosmanpaşa Physical Medicine and Rehabilitation Training and Research Hospital during the study period, who meet the inclusion and exclusion criteria, have chronic low back and/or gluteal pain, are suspected of having SCN entrapment based on clinical examination, have not benefited from conservative treatment, and voluntarily agree to participate in the study.

Based on a power analysis with 95% power, a total of 54 patients are planned to be included in the study, with 27 patients allocated to each group.

03

Conditions studied

  • Cluneal Syndrome

Keywords

  • Neuralgia
  • Peripheral Nerve Entrapment
  • low back pain
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adult patients aged 18 to 75 years presenting with chronic low back and/or gluteal pain lasting longer than three months, who are clinically suspected of having superior cluneal nerve entrapment based on physical examination findings. Eligible participants will be those who have not responded to conservative treatment and who attend the Algology Outpatient Clinic during the study period. Only patients with unilateral symptoms who meet all inclusion and exclusion criteria and who provide written informed consent will be included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 75 years
  • Chronic low back and/or gluteal pain lasting longer than 3 months
  • Localized point tenderness and/or paresthesia on palpation over the unilateral posterior iliac crest
  • Clinical suspicion of superior cluneal nerve entrapment based on physical examination
  • Failure to respond to conservative treatment
  • Ability and willingness to provide written

Exclusion criteria

Exclusion Criteria:

  • Active local or systemic infection
  • Cognitive impairment or psychiatric disorders interfering with study participation
  • History of or cancer-related pain
  • Uncontrolled diabetes mellitus or severe comorbid conditions adversely affecting general health
  • Pregnancy
  • Known allergy to the medications used in the injection
  • Prominent radicular pain associated with neurological deficit
  • History of interventional procedures applied to the lumbar region within the last 6 months
  • Initiation of another lumbar interventional or medical treatment during the follow-up period
  • Suspected bilateral superior cluneal nerve entrapment
  • Sphincter dysfunction related to neurological disease
  • Bleeding diathesis or coagulation disorders
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
59 participants (actual)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Proximal SCN Injection (Ultrasound-Guided)

    Ultrasound-guided proximal interfascial (plane block) approach for suspected superior cluneal nerve entrapment.

    Procedure: Ultrasound-guided proximal superior cluneal nerve injection

  • Distal SCN Injection (Ultrasound-Guided)

    Ultrasound-guided distal perineural approach for suspected superior cluneal nerve entrapment.

    Procedure: Ultrasound-guided distal superior cluneal nerve injection

Interventions

  • ProcedureUltrasound-guided distal superior cluneal nerve injection

    The ultrasound probe will be placed over the posterior superior iliac crest to visualize the fibro-osseous tunnel where the superior cluneal nerve passes. Using an in-plane approach, the needle will be advanced toward the target area, and the injection will be administered at the fascial exit point of the nerve. A total injectate volume of 5 cc (2 cc bupivacaine, 2 cc dexamethasone, and 1 cc normal saline) will be administered. All procedures will be performed in the prone position under standard aseptic conditions.

  • ProcedureUltrasound-guided proximal superior cluneal nerve injection

    Patients randomized to the proximal injection group will undergo ultrasound-guided injection above the iliac crest level. The target will be the plane beneath the posterior layer of the thoracolumbar fascia. Using an in-plane approach, the injectate will be delivered into the interfascial plane. A total injectate volume of 5 cc (2 cc bupivacaine, 2 cc dexamethasone, and 1 cc normal saline) will be administered under ultrasound guidance. Patient positioning and aseptic conditions will be identical to those used in the distal perineural injection group.

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale (VAS)

    Primary Outcome Measure Visual Analog Scale for Pain (VAS): Change in pain intensity assessed using the Visual Analog Scale (VAS).The VAS is a 10-cm horizontal scale ranging from 0 (no pain) to 10 (worst imaginable pain).Higher scores indicate greater pain intensity, and a reduction in VAS score represents clinical improvement.

    Time frame: Baseline, 1 month, and 3 months

Secondary outcomes

  1. Oswestry Disability Index (ODI)

    Oswestry Disability Index (ODI): Change in disability related to low back pain assessed using the Oswestry Disability Index (ODI).The validated and reliability-tested Turkish version of the ODI will be used in this study.The ODI consists of 10 items, each scored from 0 to 5, yielding a maximum total raw score of 50.The total score is converted to a percentage using the following formula:ODI percentage = (Total score / 50) × 100 Higher percentage scores indicate greater disability. Disability levels are interpreted as follows: * 0-20%: Minimal disability * 21-40%: Moderate disability * 41-60%: Severe disability * 61-80%: Crippling disability * 81-100%: Bed-bound or exaggerated symptoms A decrease in ODI percentage score indicates improvement in functional status.

    Time frame: Baseline, 1 month, and 3 months

  2. Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)

    Assessment of neuropathic pain features using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) questionnaire.The LANSS scale consists of 7 items with a total score ranging from 0 to 24.A score of ≥12 indicates the presence of neuropathic pain mechanisms.Higher scores reflect greater neuropathic pain components.

    Time frame: Baseline, 1 month, and 3 months

  3. Short Form-12 Health Survey (SF-12)

    Health-related quality of life assessed using the Short Form-12 Health Survey (SF-12).The SF-12 generates two composite scores: * Physical Component Summary (PCS) * Mental Component Summary (MCS) Both PCS and MCS scores are calculated according to standard scoring algorithms.Higher scores indicate better physical and mental health-related quality of life, respectively.In this study, PCS and MCS scores will be analyzed separately to evaluate physical and mental aspects of quality of life.

    Time frame: Baseline, 1 month, and 3 months

  4. Baseline Postural and Radiological Characteristics in Patients with Superior Cluneal Nerve Entrapment

    Baseline postural and radiological characteristics will be assessed prior to intervention in patients with superior cluneal nerve entrapment. Previously obtained standing lateral lumbosacral and pelvic radiographs will be used. Lumbar lordosis, sacral slope, lumbosacral angle, and pelvic tilt will be measured as radiographic angles in degrees on standing lateral images and categorized as decreased/normal/increased (lumbar lordosis, sacral slope, lumbosacral angle) or anterior/normal/posterior (pelvic tilt). Scoliosis will be evaluated based on physical examination and review of existing radiographs and MRI scans; when clinically indicated, standing scoliosis radiographs will be obtained. Scoliosis will be assessed using the Cobb method and recorded as present or absent. These findings will be descriptively reported.

    Time frame: Baseline (pre-intervention)

07

Study locations

1 site
  • Health Sciences University Gaziosmanpaşa Physical Medicine and Rehabilitation Training and Research Hospita
    Istanbul, 34255, Turkey (Türkiye)
08

References and documents

Publications

  • Nielsen TD, Moriggl B, Barckman J, Jensen JM, Kolsen-Petersen JA, Soballe K, Borglum J, Bendtsen TF. Randomized trial of ultrasound-guided superior cluneal nerve block. Reg Anesth Pain Med. 2019 May 6:rapm-2018-100174. doi: 10.1136/rapm-2018-100174. Online ahead of print. PubMed 31061111 ↗
  • Bodner G, Platzgummer H, Meng S, Brugger PC, Gruber GM, Lieba-Samal D. Successful Identification and Assessment of the Superior Cluneal Nerves with High-Resolution Sonography. Pain Physician. 2016 Mar;19(3):197-202. PubMed 27008294 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared due to institutional data protection policies and the absence of participant consent for data sharing beyond the scope of the current study.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Jul 2026, 7 months.

Of 77 non-industry observational studies under Neuralgia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's 7 months is below that.

Counting every sponsor, half of 88 studies reached it within 18 months; a quarter within 12 and three quarters within 55.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jul 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 28, 2026
StartActual
Dec 12, 2025
Primary completionActual
Jul 30, 2026
CompletionActual
Jul 30, 2026was Aug 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 16, 2026
Primary completion
Jul 1, 2026→Jul 30, 2026
Nov 16, 2026
Study completion
Aug 1, 2026→Jul 30, 2026 (actual)
Nov 16, 2026
Enrollment
54 (estimated)→59 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Completed
    Primary completion Jul 1, 2026→Jul 30, 2026
    Study completion Aug 1, 2026→Jul 30, 2026 (now actual)
    Enrollment 54 (estimated)→59 (actual)
    + 5 other changes: identifiers, verification date, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07372430
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Dec 12, 2025
Primary completion
Jul 30, 2026
Completion
Jul 30, 2026
Last update
Nov 16, 2026

Study contacts

Tugce Yavuz Mollavelioglu, MD
study chair · Gaziosmanapasa Educational and Training Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion